Radiochemical separation of no-carrier-added 186 Re from proton irradiated tungsten target
- PDF / 657,596 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 88 Downloads / 180 Views
Radiochemical separation of no‑carrier‑added 186Re from proton irradiated tungsten target Ramu Ram1 · Rubel Chakravarty1,2 · Sachin Jadhav1 · Sudipta Chakraborty1,2 · K. C. Jagadeesan1 · S. V. Thakare1 · Ashutosh Dash1,2 Received: 14 February 2020 © Akadémiai Kiadó, Budapest, Hungary 2020
Abstract Rhenium-186 [t½ = 3.7 d, 1.07 MeV β−-particles, 137 keV γ-ray] is an emerging radioisotope which holds tremendous potential in preparation of theranostic radiopharmaceuticals. This radioisotope was produced in a no-carrier-added form by irradiation of enriched 186W target via 186W(p, n) 186Re reaction in a pelletron. A facile radiochemical separation procedure based on selective solvent extraction in methylethyl ketone medium followed by column chromatography using mesoporous alumina sorbent has been developed to obtain 186Re in a form suitable for radiopharmaceutical preparation. This approach is expected to promote widespread utilization of this radioisotope for the benefit of cancer patients. Keywords 186Re · MEK · Mesoporous alumina · No-carrier-added · Radiochemical separation · Radiopharmaceuticals
Introduction Over the last several years, the use of new radiometals in nuclear medicine has matured from a largely obscure and exotic experimental science to an indispensable constituent of routine clinical practices for cancer management [1, 2]. This transition has been driven, in part, by the mutually essential advances in radioisotope production technology using nuclear reactors or cyclotrons, molecular imaging instruments, radiopharmaceutical science and cancer biology. Somewhat unsung is the seminal role of separation chemistry in fostering the availability of radiometals in a form suitable for formulation of radiopharmaceuticals. With the advent of the concept of “theranostics”, the utility of radiometals which emit both therapeutic β− radiation and an intense low energy γ-ray for dosimetry evaluation and therapeutic efficacy monitoring by single photon emission computed tomography (SPECT) imaging technique, is gaining prevalence [2]. This is particularly because the diagnostic and therapeutic versions of the radiopharmaceuticals * Rubel Chakravarty [email protected]; [email protected] 1
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400 085, India
Homi Bhabha National Institute, Anushaktinagar, Mumbai 400 094, India
2
prepared using such radiometals are the same and therefore the basic requirement of “personalized medicine” can be attained for maximum benefit of the cancer patients. An essential requirement in this endeavor is the availability of radiometals in NCA form for preparation of receptor specific and molecularly targeted radiopharmaceuticals. For this purpose, it is necessary to identify suitable production routes and develop efficient radiochemical separation procedures for obtaining the radiometals in NCA form meeting stringent purity requirements for radiopharmaceutical preparation. Among the theranostic radiometals, 186Re is gaining prominence b
Data Loading...
